Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial … Read more
Entera Bio Ltd (ENTX) - Total Assets
Latest total assets as of September 2025: $17.41 Million USD
Based on the latest financial reports, Entera Bio Ltd (ENTX) holds total assets worth $17.41 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Entera Bio Ltd - Total Assets Trend (2015–2024)
This chart illustrates how Entera Bio Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Entera Bio Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Entera Bio Ltd's total assets of $17.41 Million consist of 95.6% current assets and 4.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 92.2% |
| Accounts Receivable | $126.00K | 1.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Entera Bio Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Entera Bio Ltd's current assets represent 95.6% of total assets in 2024, an increase from 69.2% in 2015.
- Cash Position: Cash and equivalents constituted 92.2% of total assets in 2024, up from 43.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 23.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 1.3% of total assets.
Entera Bio Ltd Competitors by Total Assets
Key competitors of Entera Bio Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Entera Bio Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Entera Bio Ltd generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Entera Bio Ltd is currently not profitable relative to its asset base.
Entera Bio Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.83 | 6.61 | 4.95 |
| Quick Ratio | 10.83 | 6.61 | 4.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $15.44 Million | $ 6.23 Million | $ 7.27 Million |
Entera Bio Ltd - Advanced Valuation Insights
This section examines the relationship between Entera Bio Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.53 |
| Latest Market Cap to Assets Ratio | 4.48 |
| Asset Growth Rate (YoY) | -20.2% |
| Total Assets | $9.39 Million |
| Market Capitalization | $42.05 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Entera Bio Ltd's assets at a significant premium ( 4.48x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Entera Bio Ltd's assets decreased by 20.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Entera Bio Ltd (2015–2024)
The table below shows the annual total assets of Entera Bio Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $9.39 Million | -20.19% |
| 2023-12-31 | $11.77 Million | -10.38% |
| 2022-12-31 | $13.13 Million | -49.49% |
| 2021-12-31 | $25.99 Million | +167.30% |
| 2020-12-31 | $9.72 Million | -41.79% |
| 2019-12-31 | $16.70 Million | +25.20% |
| 2018-12-31 | $13.34 Million | +0.47% |
| 2017-12-31 | $13.28 Million | +111.23% |
| 2016-12-31 | $6.29 Million | +128.83% |
| 2015-12-31 | $2.75 Million | -- |